Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Dyslipidemia is a critical risk factor for cardiovascular diseases
Dr. Sanjay Behari, Director of Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, as the President of the Medical Assessment and Rating Board
Subscribe To Our Newsletter & Stay Updated
